Avalyn Pharmaceuticals

Avalyn Pharma is a private, clinical-stage biotech focused on transforming the treatment of rare lung diseases through localized inhaled drug delivery. Its pipeline features two Phase 2 assets, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), and a preclinical fixed-dose combination, AP03, aiming to improve upon the tolerability limitations of current oral therapies. Led by an experienced team with deep respiratory and corporate development expertise, the company has raised over $275 million from a syndicate of top-tier life science investors. Avalyn is positioned to address a significant unmet need in a market with established systemic therapies but substantial side-effect burdens.

Platform for developing targeted inhaled formulations of small molecule drugs, designed to deliver therapy directly to lung tissue to enhance efficacy and reduce systemic side effects.

Avalyn competes directly with Roche (pirfenidone) and Boehringer Ingelheim (nintedanib), which dominate the IPF market with oral therapies. Its competitive edge is based on improved tolerability via localized delivery. It may also face future competition from other companies developing novel oral or inhaled anti-fibrotics.